Elevated Risk of Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus Patients Treated with Azathioprine
Clinical Scorecard: Elevated Risk of Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus Patients Treated with Azathioprine
At a Glance
Category Detail
Condition Intrahepatic Cholestasis of Pregnancy (ICP) Key Mechanisms Association with bile acid accumulation and thiopurine metabolism. Target Population Pregnant women with Systemic Lupus Erythematosus (SLE) treated with Azathioprine. Care Setting Multicenter prospective cohort study.
Key Highlights
ICP incidence in the U.S. is 0.5% to 1.5%. Bile acids >40 μmol/L significantly increase fetal risks. Azathioprine (AZA) exposure linked to a three-fold increased risk of ICP in SLE. Thiopurine metabolites measured to assess risk in AZA-exposed pregnancies. Standardized data collection on demographics, comorbidities, and outcomes. Guideline-Based Recommendations
Diagnosis
ICP diagnosed by pruritus and elevated bile acids (>10 μmol/L). Management
Treatment with ursodeoxycholic acid (UDCA) and planned early delivery. Monitoring & Follow-up
Regular assessment of bile acids and liver function tests in pregnant women with SLE on AZA. Risks
Increased risks of spontaneous and iatrogenic preterm labor, meconium-stained amniotic fluid, and stillbirth. Patient & Prescribing Data
Pregnant women with SLE requiring immunosuppressive therapy.
Monitoring thiopurine metabolites may help assess risk of ICP.
Clinical Best Practices
Conduct thorough risk assessments for ICP in SLE pregnancies treated with AZA. Implement early delivery strategies for women diagnosed with ICP. Related Resources & Content
